

Daftar pustaka

- Association, B.T. 2007. *Guidelines for the management of thyroid cancer*. 2th ed. London: Royal College of Physicians.
- Baloch, Z.W., Fleisher, S., Livolsi, V.A. & Gupta, P.K. 2002. Diagnosis of “follicular neoplasm”: A gray zone in thyroid fine-needle aspiration cytology. *Diagnostic Cytopathology*, 26(1): 41–44.
- Beasley, M.J. 2012. Lymphoma of the Thyroid and Head and Neck. *Clinical Oncology*, 24(5): 345–351.
- Boelaert, K. 2009. Commentary The association between serum TSH concentration and thyroid cancer. *Society*, (July): 1–21.
- Boelaert, K., Horacek, J., Holder, R.L., Watkinson, J.C., Sheppard, M.C. & Franklyn, J.A. 2006. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. *Journal of Clinical Endocrinology and Metabolism*, 91(11): 4295–4301.
- Cooper, D.S., Doherty, G.M., Haugen, B.R., Kloos, R.T., Lee, S.L., Mandel, S.J., Mazzaferri, E.L., McIver, B., Sherman, S.I. & Tuttle, R.M. 2006. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Taskforce. *Thyroid*, 16(2): 109–142.
- Custodia G, Ji. & Santisteban, P. 2007. TSH Signalling and Cancer. *Arq Bras Endocrinol Metab*, 51: 654–671.
- Davies, L. & Welch, H.G. 2006. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002. *JAMA*, 295(18): 2164.
- Ensley, J.F., Gutkind, S., Jacobs, J.A. & Lippman, S. 2003. *Head and neck cancer: emerging perspectives*. Gulf Professional Publishing.
- Evans, P.H.R., Montgomery, P.Q. & Gullane, P.J. 2009. *Principles and Practice of Head and Neck Surgery and Oncology, Second Edition*. CRC Press.
- Farina, A.R. & Mackay, A.R. 2014. Gelatinase B/MMP-9 in tumour pathogenesis and progression. *Cancers*, 6(1): 240–296.
- Fiore, E., Rago, T., Provenzale, M.A., Scutari, M., Ugolini, C., Basolo, F., Di Coscio, G., Berti, P., Grasso, L., Elisei, R., Pinchera, A. & Vitti, P. 2009. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: Thyroid autonomy may play a protective role. *Endocrine-Related Cancer*, 16(4): 1251–1260.
- Frasca, F., Nucera, C., Pellegriti, G., Gangemi, P., Attard, M., Stella, M., Loda, M., Vella, V., Giordano, C., Trimarchi, F., Mazzon, E., Belfiore, A. & Vigneri, R. 2008. BRAF(V600E) mutation and the biology of papillary thyroid cancer. *Endocrine Related Cancer*, 15(1): 191–205.
- Gul, K., Ozdemir, D. & Dirikoc, A. 2010. Are endogenously lower serum thyroid hormones new predictors for thyroid malignancy in addition to higher serum thyrotropin ? 253–260.
- Hall, J.E. & Guyton, A.C. 2006. Pituitary Hormones and Their Control by the Hypothalamus. *Medical Physiology*, Guyton Physiology Series, 11th ed. Elsevier Saunders, hal.918–1041.
- Haugen, B.R., Alexander, E.K., Bible, K.C., Doherty, G.M., Mandel, S.J., Nikiforov, Y.E., Pacini, F., Randolph, G.W., Sawka, A.M. & Schlumberger, M. 2016. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid*, 26(1): 1–133.

- Haymart, M.R., Repplinger, D.J., Levenson, G.E., Elson, D.F., Sippel, R.S., Jaume, J.C. & Chen, H. 2008. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. *Journal of Clinical Endocrinology and Metabolism*, 93(3): 809–814.
- Jin, J., Machekano, R. & McHenry, C.R. 2010. The utility of preoperative serum thyroid-stimulating hormone level for predicting malignant nodular thyroid disease. *American Journal of Surgery*, 199(3): 294–298.
- Jung, E., Shon, H. 2011. Association between serum TSH level and papillary thyroid microcarcinoma in Korean euthyroid patients. *Thyroid*, 21(December): A93.
- Kim, S.S., Lee, B.J., Lee, J.C., Song, S.H., Kim, B.H., Son, S.M., Kim, I.J., Kim, Y.K. & Kang, Y.H. 2011. Preoperative serum thyroid stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: A single-center experience. *Endocrine*, 39(3): 259–265.
- Kondo, T., Ezzat, S. & Asa, S. 2006. *Pathogenetic mechanisms in thyroid follicular-cell neoplasia*. *Nat Rev Cancer* 6: 292–306. *Nature reviews. Cancer*, .
- Kraiem, Z. & Korem, S. 2000. Matrix metalloproteinases and the thyroid. *Thyroid : official journal of the American Thyroid Association*, 10(12): 1061–1069.
- Le, K.T., Sawicki, M.P., Wang, M.B., Hershtman, J.M. & Leung, A.M. 2016. High Prevalence of Agent Orange Exposure Among Thyroid Cancer Patients in the National VA Healthcare System. *Endocrine Practice*, 22(6): 699–702.
- Lee, G.A. & Umesh, M. 2011. Disorders of the Thyroid Gland. *CURRENT Diagnosis & Treatment Otolaryngology--Head and Neck Surgery, Third Edition*, LANGE CURRENT Series, 3th ed. New York: McGraw-hill, hal.571–591.
- Lemmon, M.A. & Schlessinger, J. 2010. Cell signaling by receptor tyrosine kinases. *Cell*, 141(7): 1117–1134.
- Marecko, I., Cvejic, D., Selemetjev, S., Paskas, S., Tatic, S., Paunovic, I. & Savin, S. 2014. Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration. *Croatian medical journal*, 55(2): 128–37.
- Mazzaferri, E.L. & Kirwan, R.J.A.J. 2006. Endocrine Tumors. *Essentials of Thyroid Cancer Management*, Cancer treatment and research. Springer US, hal.278–323.
- McDougall, I.R. 2006. *Management of thyroid cancer and related nodular disease*. Springer Science & Business Media.
- McLeod, D.S.A., Watters, K.F., Carpenter, A.D., Ladenson, P.W., Cooper, D.S. & Ding, E.L. 2012. Thyrotropin and thyroid cancer diagnosis: A systematic review and dose-response meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, 97(8): 2682–2692.
- Moon, J.H., Ahn, S., Seo, J., Han, J.W., Kim, K.M.K.W., Choi, S.H., Lim, S., Park, Y.J., Park, D.J., Kim, K.M.K.W. & Jang, H.C. 2014. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma. *The Journal of Clinical Endocrinology and Metabolism*, 99(10): 3782–3789.
- Moon, S.-S. & Lee, Y.-S. 2011. Serum thyrotropin as a risk factor for thyroid malignancy in euthyroid subjects with thyroid micronodule. (November): 1–5.
- Morris, L.G.T., Sikora, A.G., Tosteson, T.D. & Davies, L. 2013. The Increasing Incidence of Thyroid Cancer: The Influence of Access to Care. *Thyroid*, 23(7): 885–891.
- Powell, E., Piwnica-Worms, D. & Helen, P.-W. 2013. NIH Public Access. *Cancer Discov*, 31(9): 1713–1723.
- Pujol, P., Daures, J.-P., Nsakala, N., Baldet, L., Bringer, J. & Jaffiol, C. 1996. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer.

- The Journal of Clinical Endocrinology & Metabolism*, 81(12): 4318–4323.
- Robinson, D.R., Wu, Y.-M. & Lin, S.-F. 2000. The protein tyrosine kinase family of the human genome. *Oncogene*, 19(49): 5548–5557.
- Rubin, P. & Hansen, J.T. 2012. *TNM staging atlas with oncoanatomy*. Wolters Kluwer Health/Lippincott Williams & Wilkins.
- Soh, E.Y., Sobhi, S.A., Wong, M.G., Meng, Y.G., Siperstein, A.E., Clark, O.H. & Duh, Q.Y. 1996. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. *Surgery*, 120(6): 944–947.
- Striker, T. & Vinay, K. 2013. Neoplasia. *Robbins Basic Pathology*, 8 th. Philadelphia: Elsevier, hal.173–224.
- Tuttle, R.M., Haugen, B. & Perrier, N.D. 2017. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? *Thyroid*, 27(6): 751–756.
- Weir, H.K., Thompson, T.D., Soman, A., Miller, B. & Leadbetter, S. 2015. The past, present, and future of cancer incidence in the United States: 1975 through 2020. *Cancer*, 121(11): 1827–1837.
- Williams, R.H. & Wilson, J.D. 1998. The Thyroid Gland. *Williams Textbook of Endocrinology*, Williams Textbook of Endocrinology, 9th ed. Saunders, hal.389–402.
- Yeh, M.W., Bauer, A.J., Bernet, V.A., Ferris, R.L., Loevner, L.A., Mandel, S.J., Orloff, L.A., Randolph, G.W. & Steward, D.L. 2015. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. *Thyroid*, 25(1): 3–14.
- Zafon, C., Obiols, G., Baena, J.A., Castellví, J., Dalama, B. & Mesa, J. 2012. Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size. *Journal of Thyroid Research*, 2012.
- Zhang, I., DeMauro-Jablonski, S. & Ferris, R.L. 2014. Treatment of Thyroid Neoplasm. *Bailey's Head and Neck Surgery: Otolaryngology*. Wolters Kluwer Health, hal.2115–2129.